News
Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback